Marty Shtrubel
Apr 08, 2021
No one likes being given the wrong information. Investors reacted in dismay and sent Fibrogen (FGEN) shares deep into the red following the company’s embarrassing announcement. The biotech company said it had gotten the analysis for its therapy for sufferers of anemia related to chronic kidney disease, well, wrong.
The company said that the data from the late-stage study of roxadustat had “included post-hoc changes to the stratification factors.” The data was used instead of the original stratification plan, in presentations and several press releases last year. Leerink analyst Geoff Porges says it was also “presumably” used in the submission to the FDA.
Management said it was carrying out an “internal review to ensure such issues do not occur in the future.”
The major “oops,” says Porges, is nothing less than stunning.
“The re-statement reduced the benefit from roxa vs controls in every case, erased the appearance of superiority over ESAs in incident dialysis patients, and increased the apparent risk of a negative effect of roxa on CV safety in non-dialysis patients,” the analyst said. “It’s not clear to us whether the company previously mis-presented, or mis-represented, the results of the analysis, but either way this disclosure, long after the NDA had been submitted, and after both PDUFA dates have passed, raises questions about the reception that the company will get when they appear at the newly announced FDA Cardio Renal Advisory Committee meeting on July 15.”
The disclosure is also sure to raise several questions amongst investors. Does roxadustat still have any chance of approval? Will it affect the company’s partnership with AstraZeneca? Will management survive?
As far as Roxadustat is concerned, Porges anticipates one of two likely outcomes. If, as management has suggested, the FDA was informed of the issue and already aware of the “different statistical analyses,” then it “could approach the review without prejudice.” The drug could then even be granted approval by the end of the summer.
On the other hand, if the FDA has only recently been notified of the issue, then Porges says, there is the “real possibility that the agency will require a complete audit of all of the trial results, endpoints and analyses in the database, which could require many months.”
Porges takes the prudent approach and now does not expect approval until 1Q22.
Interestingly, though, Porges sticks to an Outperform (i.e. Buy) rating, and while the price target is reduced from $64 to $56, the revised figure still implies upside of a hefty 198%. (To watch Porges’ track record, click here)
Overall, TipRanks analysis of 9 analyst ratings shows an indecision between the bulls and the naysayers on FGEN: 4 suggest Buy, 4 say Hold, and only one recommends Sell. Importantly, the 12-month average price target stands at $47.17, marking nearly 151% in upside potential from where the stock is currently trading. (See FGEN stock analysis on TipRanks)
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent FGEN News
- FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A • GlobeNewswire Inc. • 04/24/2024 08:02:00 PM
- FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer • GlobeNewswire Inc. • 04/02/2024 09:46:47 PM
- FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/26/2024 11:00:00 AM
- FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:19:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:18:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:17:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 09:08:13 PM
- FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/26/2024 09:06:00 PM
- FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea • GlobeNewswire Inc. • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:33:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:29:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:28:24 AM
- FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/20/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:37:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 01:08:37 AM
- FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024 • GlobeNewswire Inc. • 02/05/2024 12:00:00 PM
- FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer • GlobeNewswire Inc. • 01/25/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 12:28:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/11/2023 09:21:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/11/2023 09:20:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/11/2023 09:19:23 PM
- FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting • GlobeNewswire Inc. • 12/09/2023 10:02:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2023 09:11:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 09:05:53 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM